Metastatic triple-negative breast cancer – current treatment strategies in the Nordics: a modified Delphi study

Keyphrases

• Treatment Strategy 100%
• Current Treatment 100%
• Modified Delphi Study 100%
• Metastatic Triple-negative Breast Cancer 100%
• Chemotherapy 75%
• Later-line 75%
• Breast Cancer Patients 50%
• PARP Inhibitor (PARPi) 50%
• Programmed Death-ligand 1 (PD-L1) 50%
• Checkpoint Inhibitors 50%
• Sacituzumab Govitecan 50%
• Sweden 25%
• Denmark-Norway 25%
• Iceland 25%
• Finland 25%
• Clinical Treatment 25%
• Treatment Patterns 25%
• Steering Committee 25%
• New Treatment Options 25%
• Clinical Scenarios 25%
• International Guidelines 25%
• Oncologists 25%
• Therapeutic Advances 25%
• Reaching Consensus 25%
• Modified Delphi Method 25%
• Medical Experts 25%
• Treatment Preferences 25%
• Treatment Line 25%
• Germline BRCA mutation 25%

Medicine and Dentistry

• Triple Negative Breast Cancer 100%
• Programmed Death-Ligand 1 50%
• PARP Inhibitor 50%
• Sacituzumab Govitecan 50%
• BRCA Mutation 25%
• Oncologist 25%
• Germ Cell 25%
• Diseases 25%
• Preference 25%

Biochemistry, Genetics and Molecular Biology

• Poly ADP Ribose Polymerase 100%
• PD-L1 100%
• Germline 50%
• Germ Cell 50%